Coherus Oncology (CHRS) Payables (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Payables data on file, last reported at $11.5 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 82.91% year-over-year to $11.5 million; the trailing twelve-month figure through Mar 2026 stood at $11.5 million (down 82.91% YoY), and the FY2025 full-year result was $9.9 million, down 76.44% from the prior year.
• Payables climbed to $11.5 million in Q1 2026, from $9.9 million in the prior quarter.
• In the past five years, Payables ranged from a high of $86.0 million in Q2 2024 to a low of $9.9 million in Q4 2025.
• A 5-year average of $31.4 million and a median of $29.4 million in 2023 frame the typical range for Payables.
• Across the five-year window, Payables sank 92.17% in 2022 and surged 274.02% in 2023, its largest moves.
• Tracing CHRS's Payables over 5 years: stood at $11.5 million in 2022, then soared by 205.56% to $35.2 million in 2023, then gained by 19.47% to $42.1 million in 2024, then slumped by 76.44% to $9.9 million in 2025, then gained by 15.77% to $11.5 million in 2026.
• Business Quant data shows CHRS's Payables at $11.5 million in Q1 2026, $9.9 million in Q4 2025, and $24.9 million in Q3 2025.